SEC Form 4 · accession 0001209191-16-122639
Insys Therapeutics, Inc. · INSY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Darryl S Baker
Officer — Chief Financial Officer
Period of report
May 23, 2016
Accepted (ET)
May 23, 2016 · 4:40 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001516479
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 23, 2016 | M | 10,000 | $13.57 | A | 21,030 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3,F1,F2 | $13.57 | May 23, 2016 | M | 10,000 | D | — | Aug 6, 2024 | Common Stock | 10,000 | 80,000 | D |
Explanation of responses
- F1The option was previously reported as an option to purchase 45,000 shares at an exercise price of $27.14 per share, and has been adjusted to reflect the 2-for-1 forward stock split effected by the Issuer on June 5, 2015.
- F2The option vests in 48 equal monthly installments and will be fully vested and exercisable on August 7, 2018.
- F3On June 5, 2015, the Issuer effected a 2-for-1 forward stock split, resulting in the reporting person's ownership of 45,000 additonal options.